ESC 365 - Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - CON

Open Access

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - CON

Session: Controversies in channelopathy

Topic: Brugada Syndrome

Speaker: Professor S. Viskin (Tel Aviv, IL)

Event: EHRA 2018

Congress Session

About the speaker

Professor Samuel Viskin

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

7 presentations

0 follower

11 more presentations in this session

Opening question

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - PRO

Speaker: Professor V. Probst (Nantes, FR)

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal PRO

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal CON

Chairperson conclusion & Closing question

Access the full session

Controversies in channelopathy

Speakers: Professor S. Viskin, Professor V. Probst

About the event

EHRA 2018

18 March - 20 March 2018

Sessions Presentations

Congress

This platform is supported by